Your browser is no longer supported. Please, upgrade your browser.
Settings
HALO Halozyme Therapeutics, Inc. daily Stock Chart
HALO [NASD]
Halozyme Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.36 Insider Own1.00% Shs Outstand149.76M Perf Week-1.75%
Market Cap2.44B Forward P/E- EPS next Y-0.43 Insider Trans0.00% Shs Float132.80M Perf Month-2.04%
Income-51.10M PEG- EPS next Q-0.14 Inst Own86.60% Short Float5.62% Perf Quarter2.00%
Sales177.90M P/S13.71 EPS this Y-223.50% Inst Trans-1.27% Short Ratio8.69 Perf Half Y-0.06%
Book/sh1.80 P/B9.05 EPS next Y-2.40% ROA-11.40% Target Price20.56 Perf Year-6.97%
Cash/sh2.19 P/C7.42 EPS next 5Y- ROE-20.40% 52W Range13.24 - 18.85 Perf YTD11.35%
Dividend- P/FCF- EPS past 5Y5.40% ROI-18.60% 52W High-12.63% Beta1.76
Dividend %- Quick Ratio2.70 Sales past 5Y22.60% Gross Margin93.40% 52W Low24.40% ATR0.45
Employees281 Current Ratio2.90 Sales Q/Q84.10% Oper. Margin-24.00% RSI (14)47.74 Volatility2.57% 2.63%
OptionableYes Debt/Eq0.41 EPS Q/Q106.30% Profit Margin-28.70% Rel Volume0.42 Prev Close16.29
ShortableYes LT Debt/Eq0.07 EarningsAug 06 AMC Payout- Avg Volume858.17K Price16.47
Recom2.60 SMA20-2.46% SMA502.11% SMA2001.98% Volume156,044 Change1.10%
Oct-19-18Resumed Piper Jaffray Neutral
May-11-18Downgrade Barclays Equal Weight → Underweight $19
Jan-24-18Initiated Goldman Neutral
Oct-16-17Reiterated Piper Jaffray Overweight $26 → $29
Jan-06-17Downgrade Citigroup Buy → Neutral
Nov-03-16Initiated Deutsche Bank Buy $12
Dec-04-15Initiated Wells Fargo Outperform
Nov-18-15Initiated Citigroup Buy
Sep-22-15Initiated Barclays Overweight $27
Jun-22-15Reiterated JP Morgan Overweight $20 → $25
Mar-03-15Reiterated UBS Buy $16 → $21
Feb-18-15Reiterated MLV & Co Buy $15 → $20
Jan-08-15Reiterated MLV & Co Buy $12 → $15
Dec-24-14Initiated MLV & Co Buy $12
Jun-12-14Upgrade UBS Neutral → Buy $14 → $16
Jan-10-14Reiterated Barclays Equal Weight $12 → $15
Nov-11-13Reiterated UBS Neutral $8 → $14
Nov-11-13Reiterated Barclays Equal Weight $8 → $12
Aug-02-13Downgrade Barclays Overweight → Equal Weight $9 → $8
May-01-13Reiterated UBS Neutral $8 → $6.50
Jul-22-19 10:16AM  Alexion (ALXN) to Report Q2 Earnings: What's in the Cards? Zacks
Jul-19-19 07:00AM  Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology PR Newswire
Jul-17-19 08:00AM  Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology PR Newswire
Jul-12-19 11:59AM  Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology PR Newswire
Jul-04-19 01:44PM  The Halozyme Therapeutics (NASDAQ:HALO) Share Price Has Gained 99% And Shareholders Are Hoping For More Simply Wall St.
Jun-25-19 08:00AM  Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Technology PR Newswire
Jun-12-19 05:04PM  Edited Transcript of HALO earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
Jun-11-19 04:37PM  Is Halozyme Therapeutics, Inc. (HALO) A Good Stock To Buy? Insider Monkey
Jun-04-19 08:00AM  Halozyme To Participate In Upcoming Investor Conferences PR Newswire
Jun-03-19 01:34PM  Is Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
May-22-19 01:05AM  Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement PR Newswire
May-21-19 07:46AM  Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay? Zacks
May-13-19 08:01AM  Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019 PR Newswire
May-07-19 09:23PM  Halozyme Therapeutics Inc (HALO) Q1 2019 Earnings Call Transcript Motley Fool
06:05PM  Halozyme Therapeutics (HALO) Matches Q1 Earnings Estimates Zacks
05:01PM  Halozyme Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Halozyme Reports First Quarter 2019 Results PR Newswire
02:30AM  Halozyme Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-06-19 08:00AM  Halozyme Names Dr. Alison A. Armour As Senior Vice President Of Research And Development PR Newswire
May-01-19 10:29AM  How Halozyme Therapeutics, Inc. (NASDAQ:HALO) Can Impact Your Portfolio Volatility Simply Wall St.
Apr-30-19 03:14PM  Heres What Hedge Funds Think About Halozyme Therapeutics, Inc. (HALO) Anymore Insider Monkey
10:32AM  Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? Zacks
07:00AM  REPEAT/Halo Labs Begins Trading on the OTCQX Market Business Wire
03:00AM  Halo Labs Begins Trading on the OTCQX Market Business Wire
Apr-23-19 04:01PM  Halozyme To Host First Quarter 2019 Financial Results Webcast And Conference Call PR Newswire
Apr-02-19 11:36AM  Need To Know: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Insiders Have Been Selling Shares Simply Wall St.
Mar-23-19 12:14PM  3 Cancer Treatment Stocks to Buy in March Motley Fool
Mar-11-19 07:43PM  Avid Bioservices, Inc. (CDMO) Q3 2019 Earnings Conference Call Transcript Motley Fool
Mar-10-19 10:45AM  2 Stocks You Definitely Should Consider Shorting This Week TheStreet.com
Mar-08-19 09:58AM  Halo Labs Announces Hush and Gilt Product Lines to Be Distributed by C4 Distro in Southern California Business Wire
01:19AM  Halo Labs Announces Hush and Gilt Product Lines to Be Distributed by C4 Distro in Southern California Business Wire
Mar-07-19 10:08AM  Halo Labs Announces Short Form Prospectus Offering of Convertible Debenture Units Business Wire
Mar-05-19 04:01PM  Halo Labs Awarded Annual Cannabis Manufacturing License by California, among the First to Implement Track and Trace (METRC) Business Wire
Mar-04-19 09:54AM  Top Ranked Momentum Stocks to Buy for March 4th Zacks
08:01AM  Halozyme To Participate In Upcoming Investor Conferences PR Newswire
Mar-01-19 04:33PM  Halo Labs Reports Record Monthly Revenue of Approximately US$2.6 Million (CDN $3.4 Million) In the Shortened Month of February Business Wire
06:25AM  Edited Transcript of HALO earnings conference call or presentation 21-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Feb-28-19 11:47AM  Halozyme Announces FDA Approval Of Herceptin Hylecta PR Newswire
Feb-26-19 04:01PM  Halo Labs Successfully Launches DabTabs in Oregon and Nevada Business Wire
Feb-25-19 04:42PM  Halo Labs Signs Bulk Biomass Procurement and Bulk Extract Supply Agreement with Cannus Partners in California Business Wire
06:00AM  Halo Labs to Present at The Gravitas Growth Conference in Vancouver Business Wire
Feb-22-19 08:00AM  REPEAT/Halo Labs Commences Trading on the OTCQB Venture Market in the United States under the Symbol AGEEF Business Wire
Feb-21-19 10:09PM  Halozyme Therapeutics Inc (HALO) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:15PM  Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates Zacks
05:20PM  Halozyme Therapeutics: 4Q Earnings Snapshot Associated Press
04:32PM  Halo Labs Commences Trading on the OTCQB Venture Market in the United States under the Symbol AGEEF Business Wire
04:01PM  Halozyme Reports Fourth Quarter And Full-Year 2018 Results PR Newswire
07:32AM  The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan Benzinga
03:00AM  Halo Labs Reports Record Monthly Revenue of Approximately US$2.4 Million (CDN $3.1 Million) in January 2019 Business Wire
Feb-20-19 08:00AM  Halo Labs Announces Proposed California Acquisition, Change of Auditor and Corporate Updates Business Wire
Feb-15-19 08:20AM  Consolidated Research: 2019 Summary Expectations for Tenaris S.A, Rapid7, Halozyme Therapeutics, Cara Therapeutics, EnPro Industries, and K12 Fundamental Analysis, Key Performance Indications GlobeNewswire
Feb-14-19 10:31AM  Analysts Estimate Halozyme Therapeutics (HALO) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-12-19 11:56AM  Is Halozyme Therapeutics, Inc.s (NASDAQ:HALO) CEO Pay Fair? Simply Wall St.
Feb-07-19 04:01PM  Halozyme To Host Fourth Quarter And Full-Year 2018 Financial Results Webcast And Conference Call PR Newswire
Feb-04-19 12:45PM  Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up Zacks
01:00AM  argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology PR Newswire
Jan-31-19 07:26PM  Alexion (ALXN) to Report Q4 Earnings: What's in the Cards? Zacks
08:00AM  Halo Labs Provides Operational Update & Announces Closing of Promissory Note Business Wire
Jan-29-19 11:10AM  Alexion's Ultomiris Meets Primary Endpoint in aHUS Study Zacks
Jan-23-19 06:30AM  Halo Labs Announces Dab Tabs to Launch in Leading Retailer Med Men in California and Nevada Business Wire
Jan-11-19 06:55AM  Today's Research Reports on Trending Tickers: Halozyme Therapeutics and Alnylam Pharmaceuticals ACCESSWIRE
Jan-09-19 01:30PM  Halozyme Provides 2019 Pipeline Update And Financial Guidance At 37th Annual JP Morgan Healthcare Conference PR Newswire
Jan-07-19 11:51AM  Is Halozyme Therapeutics, Inc.s (NASDAQ:HALO) 19% Better Than Average? Simply Wall St.
Dec-27-18 06:21PM  Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure Zacks
07:25AM  Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor Therapeutics, Appian, Yext, Agile Therapeutics, and Corbus Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
Dec-26-18 08:00AM  Halozyme Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference PR Newswire +7.50%
Dec-24-18 09:26AM  Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder Zacks
Dec-19-18 08:00AM  Halo Labs Announces Insider Purchases of $135,000 Business Wire
Dec-14-18 10:34PM  Hedge Funds Are Betting On Halozyme Therapeutics, Inc. (HALO) Insider Monkey
Dec-12-18 08:00AM  Halo Labs Announces Strategic Partnership in Lesotho Africa Business Wire
Dec-05-18 09:38AM  Halo Labs Announces Start of Production in California Business Wire
Dec-04-18 09:36AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Halozyme Therapeutics, Inc. (HALO) ACCESSWIRE -7.12%
Dec-03-18 05:05PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Halozyme Therapeutics, Inc. HALO GlobeNewswire
Nov-29-18 04:16PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Halozyme Therapeutics, Inc. - HALO PR Newswire
02:33PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Halozyme Therapeutics, Inc. (HALO) GlobeNewswire
10:43AM  What You Must Know About Halozyme Therapeutics Incs (NASDAQ:HALO) Financial Strength Simply Wall St.
Nov-27-18 07:32AM  The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial Benzinga -7.42%
06:55AM  Today's Research Reports on Trending Tickers: Halozyme Therapeutics and Loxo Oncology ACCESSWIRE
Nov-26-18 04:05PM  Halozyme Announces Change In Primary Endpoint For HALO-301 To Overall Survival PR Newswire
Nov-19-18 05:00AM  Edited Transcript of HALO earnings conference call or presentation 6-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-16-18 07:00AM  Today's Research Reports on Trending Tickers: Loxo Oncology and Halozyme Therapeutics ACCESSWIRE
Nov-14-18 06:10AM  Halozyme Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks
Nov-09-18 08:00AM  Halo Labs Announces Dispensary Sales for the Month of October Business Wire
Nov-08-18 07:40AM  Report: Exploring Fundamental Drivers Behind Entergy, BLACKLINE INC, HollyFrontier, Hill-Rom, Apache, and Halozyme Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-06-18 07:05PM  Halozyme Therapeutics (HALO) Reports Q3 Loss, Misses Revenue Estimates Zacks
06:02PM  Halozyme Therapeutics: 3Q Earnings Snapshot Associated Press
04:05PM  Halozyme Reports Third Quarter 2018 Financial Results PR Newswire
09:23AM  A Preview Of Halozyme Therapeutics Q3 Earnings Benzinga
08:00AM  Halozyme Names Albert Kildani As Vice President Investor Relations And Corporate Communications PR Newswire
Nov-01-18 08:00AM  Halo Labs Announces Launch of Edibles in Oregon Business Wire +5.09%
Oct-30-18 08:00AM  Halozyme Licenses New ENHANZE® Targets For $25 Million Upfront Payment, Future Milestones And Royalties PR Newswire
Oct-26-18 08:00AM  Today's Research Reports on Trending Tickers: Halozyme Therapeutics and Exelixis ACCESSWIRE
Oct-25-18 08:00AM  Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology PR Newswire +6.07%
Oct-23-18 10:38AM  Halo Labs Inc. Opens NEO Business Wire
Oct-22-18 08:00AM  Halozyme Provides Summary Results Of Data For PEGPH20 Combination Treatments Presented At ESMO 2018 Congress PR Newswire
Oct-17-18 11:06AM  Halo Labs Signs US$2 Million Per Month Extraction Agreement with Falcon International to Supply Cannabis Oil in California Business Wire
09:00AM  Market Trends Toward New Normal in Halozyme Therapeutics, Fitbit, Iconix Brand Group, Leap Therapeutics, LightPath Technologies, and Capricor Therapeutics Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Oct-15-18 10:41AM  Does Halozyme Therapeutics Incs (NASDAQ:HALO) PE Ratio Signal A Selling Opportunity? Simply Wall St.
Oct-10-18 04:05PM  Halozyme To Host Third Quarter 2018 Financial Results Conference Call PR Newswire
08:00AM  Halo Labs Launches 3 Brands in Nevada and Provides Update on Nevada Operations Business Wire
Halozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to enhance resorption of radiopaque agents. The company also develops PEGPH20, a therapy that is in Phase III clinical trial for pancreatic ductal adenocarcinoma; in Phase Ib clinical trial for non-small cell lung cancer; in Phase Ib/II clinical trial for patients with previously treated metastatic pancreatic ductal adenocarcinoma; in Phase Ib/II clinical trial for patients with gastric cancer; and in Phase Ib/II for cholangiocarcinoma and gall bladder cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. The company was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stelzer LaurieSVP, Chief Financial OfficerJun 15Option Exercise0.006,875085,370Jun 17 08:19 AM
Chondros DimitriosSVP, Chief Medical OfficerJun 01Option Exercise0.002,043040,618Jun 03 05:22 PM
LEONHARDT HARRY JSVP, GCApr 13Option Exercise0.006,875068,750Apr 15 04:08 PM
Chondros DimitriosSVP, Chief Medical OfficerFeb 22Option Exercise0.003,884039,918Feb 22 07:04 PM
LEONHARDT HARRY JSVP, GCFeb 22Option Exercise0.0011,392065,814Feb 22 07:03 PM
Torley HelenPresident and CEOFeb 22Option Exercise0.0039,3540436,091Feb 22 07:02 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 22Option Exercise0.0011,392082,434Feb 22 07:03 PM
Chondros DimitriosSVP, Chief Medical OfficerFeb 14Option Exercise0.006,790038,389Feb 15 05:36 PM
LEONHARDT HARRY JSVP, GCFeb 14Option Exercise0.007,809057,122Feb 15 05:34 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 14Option Exercise0.007,809073,742Feb 15 05:33 PM
Torley HelenPresident and CEOFeb 14Option Exercise0.0028,7300410,981Feb 15 05:32 PM
Torley HelenPresident and CEOFeb 06Option Exercise0.0031,2500396,798Feb 06 06:02 PM
LEONHARDT HARRY JSVP, GCFeb 03Option Exercise0.0015,413054,971Feb 05 04:11 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 03Option Exercise0.0023,119074,250Feb 05 04:10 PM
Torley HelenPresident and CEOFeb 03Option Exercise0.0055,4870384,973Feb 05 04:09 PM
KIRK RANDAL J10% OwnerAug 28Sale18.02432,2497,789,1271,897,610Aug 28 05:25 PM
KIRK RANDAL J10% OwnerAug 27Sale18.22109,3771,992,8492,154,470Aug 28 05:25 PM
KIRK RANDAL J10% OwnerAug 24Sale18.20103,3721,881,3702,219,466Aug 28 05:25 PM
KIRK RANDAL J10% OwnerAug 23Sale18.48251,3354,644,6712,280,894Aug 23 04:33 PM
KIRK RANDAL J10% OwnerAug 22Sale17.49781,88113,675,0992,430,247Aug 23 04:33 PM
KIRK RANDAL J10% OwnerAug 21Sale17.15161,2462,765,3692,894,871Aug 23 04:33 PM
KIRK RANDAL J10% OwnerAug 16Sale17.2495,3631,644,0582,985,054Aug 16 05:16 PM
KIRK RANDAL J10% OwnerAug 15Sale17.1591,5411,569,9283,041,722Aug 16 05:16 PM
KIRK RANDAL J10% OwnerAug 14Sale17.36303,1685,262,9963,096,119Aug 16 05:16 PM
KIRK RANDAL J10% OwnerAug 10Sale17.08202,9593,466,5403,276,273Aug 10 05:00 PM
KIRK RANDAL J10% OwnerAug 09Sale17.48223,1273,900,2603,396,879Aug 10 05:00 PM
KIRK RANDAL J10% OwnerAug 08Sale17.52146,7182,570,4993,529,470Aug 10 05:00 PM
KIRK RANDAL J10% OwnerJul 27Sale16.9048,927826,8663,616,655Jul 27 04:35 PM
KIRK RANDAL J10% OwnerJul 26Sale17.30150,0002,595,0003,645,729Jul 27 04:35 PM
KIRK RANDAL J10% OwnerJul 25Sale17.32103,9001,799,5483,734,865Jul 27 04:35 PM